文献速递细菌感染、耐药与抗菌药物

2024年WHO淋病奈瑟菌全球实验室质量保证参考菌株及被替代的WHO淋病奈瑟菌参考菌株的表型、遗传与参考基因组特征

The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本文报告2024年WHO淋病奈瑟菌参考菌株(n=15)及全部被替代的WHO参考菌株(n=14)的表型、遗传与参考基因组特征,菌株经单分子PacBio或Oxford Nanopore及Illumina测序。2024年菌株涵盖当前及既往使用的22种抗菌药物和3种未来考虑药物的敏感与耐药表型及基因型,并包含国际传播的头孢曲松耐药、新penA突变所致头孢曲松耐药、头孢曲松联合高水平阿奇霉素耐药及马赛克MtrRCDE外排泵所致阿奇霉素耐药的新菌株。作者推荐将这些菌株用于实验室检查的内部和外部质量保证。

要点

  • 2024年WHO参考菌株共15株,含11株2016年菌株的进一步表征和4株新菌株。
  • 被替代的WHO参考菌株共14株,含11株此前未发表的菌株,均作了相同表征。
  • 2024年菌株覆盖22种当前及既往使用药物与3种未来考虑药物的敏感和耐药表型及基因型。

核心结论

  • 2024年WHO淋病奈瑟菌参考菌株推荐用于实验室检查的内部和外部质量保证,尤其是WHO GASP、EGASP及其他GASP,也用于表型和分子诊断、耐药预测、药效学、流行病学、研究及WGS分析中的完整参考基因组。

研究设计与样本

  • 对2024年WHO淋病奈瑟菌参考菌株(n=15)和全部被替代的WHO参考菌株(n=14)进行表型和基因组表征,测序采用单分子PacBio或Oxford Nanopore及Illumina测序。

主要发现

  • 2024年WHO参考菌株涵盖当前及既往使用的22种抗菌药物和未来考虑的3种抗菌药物的全部可得敏感与耐药表型及基因型。
  • 新WHO菌株包括国际传播的头孢曲松耐药、新penA突变所致头孢曲松耐药、头孢曲松联合高水平阿奇霉素耐药,以及马赛克MtrRCDE外排泵所致阿奇霉素耐药。
  • 所有菌株均报告了抗菌药物耐药性、血清群、脯氨酰亚氨基肽酶、遗传耐药决定因子、质粒类型、分子流行病学类型和参考基因组特征。

临床怎么用

  • 作者推荐2024年WHO淋病奈瑟菌参考菌株用于实验室检查的内部和外部质量保证,尤其是WHO GASP、EGASP及其他GASP。
  • 作者推荐这些菌株用于表型和分子诊断、耐药预测、药效学、流行病学、研究以及WGS分析中的完整参考基因组。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: MDR and XDR Neisseria gonorrhoeae strains remain major public health concerns internationally, and quality-assured global gonococcal antimicrobial resistance (AMR) surveillance is imperative. The WHO global Gonococcal Antimicrobial Surveillance Programme (GASP) and WHO Enhanced GASP (EGASP), including metadata and WGS, are expanding internationally. We present the phenotypic, genetic and reference genome characteristics of the 2024 WHO gonococcal reference strains (n = 15) for quality assurance worldwide. All superseded WHO gonococcal reference strains (n = 14) were identically characterized. MATERIAL AND METHODS: The 2024 WHO reference strains include 11 of the 2016 WHO reference strains, which were further characterized, and four novel strains. The superseded WHO reference strains include 11 WHO reference strains previously unpublished. All strains were characterized phenotypically and genomically (single-molecule PacBio or Oxford Nanopore and Illumina sequencing). RESULTS: The 2024 WHO reference strains represent all available susceptible and resistant phenotypes and genotypes for antimicrobials currently and previously used (n = 22), or considered for future use (n = 3) in gonorrhoea treatment. The novel WHO strains include internationally spreading ceftriaxone resistance, ceftriaxone resistance due to new penA mutations, ceftriaxone plus high-level azithromycin resistance and azithromycin resistance due to mosaic MtrRCDE efflux pump. AMR, serogroup, prolyliminopeptidase, genetic AMR determinants, plasmid types, molecular epidemiological types and reference genome characteristics are presented for all strains. CONCLUSIONS: The 2024 WHO gonococcal reference strains are recommended for internal and external quality assurance in laboratory examinations, especially in the WHO GASP, EGASP and other GASPs, but also in phenotypic and molecular diagnostics, AMR prediction, pharmacodynamics, epidemiology, research and as complete reference genomes in WGS analysis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Unemo M, Sánchez-Busó L, Golparian D, et al. The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization. J Antimicrob Chemother. 2024. PMID: 38889110. doi:10.1093/jac/dkae176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。